Name: 글로벌 시장 동향
SKU: PH5147
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 악성 중피종 치료제 시장은 2022년 2억 5,930만 달러 규모에 도달했으며, 2030년까지 5억 1,270만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 악성 중피종 치료제 시장은 예측 기간(2023~2030년) 동안 연평균 9.1%의 성장률을 기록할 것으로 예상됩니다.
악성 중피종 발병률 증가, 암 치료에 대한 인식 제고, 다양한 산업 분야에서 석면 사용 확대, 기술 혁신 등의 주요 요인들이 시장 성장을 견인할 것으로 전망됩니다.
예측 기간 동안 전 세계 악성 중피종 치료제 시장은 정교한 치료법의 개발로 더욱 성장할 것으로 예상됩니다. 또한, 다양한 제품 및 산업 분야에서 석면 사용이 증가하고 있는데, 이는 중피종 발생의 주요 원인 중 하나입니다.

시장 동향
조기 진단 및 치료를 위한 인식 제고 캠페인 강화가 시장 성장을 견인할 전망
악성 중피종은 전 세계적으로 발생률이 증가하고 있으며, 이에 따라 조기 진단 및 치료를 위한 인식 제고 캠페인이 더욱 중요해지고 있습니다. 많은 단체들이 이 질환에 대한 인식을 높이고 석면 노출 근로자들에게 악성 중피종 검진을 정기적으로 받도록 권장하고 있으며, 이는 질병의 진행을 예방하는 데 도움이 될 수 있습니다. 이러한 인식 제고는 시장 성장에 전반적으로 긍정적인 영향을 미칠 것으로 예상됩니다.
또한, 담배 소비 증가도 악성 중피종 치료제 시장 성장을 촉진하고 있습니다. 전 세계 악성 중피종 시장의 대부분 기업들은 다양한 약물을 병용 투여하는 치료법의 효과를 연구하기 위해 여러 기관과 협력하고 있습니다. 관련 기술 특허가 부족한 상황에서 많은 기업들이 다양한 약물 병용 요법에 대한 임상 연구를 진행하고 있습니다.

악성 중피종의 긴 잠복기는 시장 성장을 저해할 가능성이 높습니다.
악성 중피종의 긴 잠복기, 초기 단계에서 질병 특이적 바이오마커의 부족, 그리고 혁신적인 암 치료 기기의 개발 및 승인은 예측 기간 동안 악성 중피종 치료제 시장의 성장을 둔화시킬 수 있습니다.
COVID-19 영향 분석
전 세계 악성 중피종 치료제 시장은 COVID-19 발생으로 인해 긍정적인 영향을 받았습니다. COVID-19 상황으로 인해 여러 부문에서 의약품 수요가 증가했습니다. 제약 회사들은 공급망 관리를 크게 개선하고, 연구 개발 역량을 강화하며, 제조 관리 및 품질 관리 투자를 늘렸습니다.
부문별 분석
페메트렉세드 계열 약물 부문은 예측 기간 동안 39.1%의 시장 점유율을 차지하며 시장을 주도할 것입니다.
단일 요법보다 병용 요법에 대한 선호도는 페메트렉세드 및 병용 약물 부문의 성장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 화학요법과 방사선 치료, 표적 항체, 냉동 요법 또는 기타 면역 요법을 병용한 복합 요법은 다양한 약물의 잠재적 적응증을 확대할 것으로 예상됩니다.
이러한 복합 요법은 수술이나 방사선 치료 단독 요법에 비해 생존율을 크게 향상시키는 것을 목표로 하며, 임상 데이터는 아직 충분히 확보되지 않았습니다. 여러 제약 회사들은 종양 조절의 다양한 경로가 영향을 받는다는 사실을 발견하고, 보다 효과적인 치료법으로 복합 요법을 활용하고자 합니다. 이러한 요인들은 악성 중피종 치료제 시장의 성장을 촉진할 것으로 예상됩니다.
지역 분석
북미는 예측 기간 동안 시장을 주도할 지역입니다.
2022년 미국은 북미 시장에서 약 39.2%의 점유율을 차지하며 핵심적인 역할을 수행했습니다. 위험 요인 및 진단 절차에 대한 인식이 높아짐에 따라 북미의 악성 중피종 시장 규모는 다른 지역보다 빠르게 성장하고 있습니다. 선진적인 의료 인프라 또한 북미 악성 중피종 치료제 시장의 성장을 견인할 것으로 예상됩니다.

경쟁 환경
주요 글로벌 기업으로는 Dr. Reddy’s Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer 및 Ono Pharmaceuticals 등이 있습니다.

• 보고서 구매 이유

• 유형, 최종 사용자 및 지역별 글로벌 악성 중피종 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위해

• 모든 세그먼트를 포함한 악성 중피종 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 제공

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공

• 주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일 제공

악성 중피종 치료제 시장 보고서는 약 92개의 표, 108개의 그림, 195페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Malignant Mesothelioma Therapeutics Market reached US$ 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 512.7 million by 2030. The global malignant mesothelioma therapeutics is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).
The main industry drivers, including the rise in malignant mesothelioma instances, rising cancer treatment awareness, expanding use of asbestos in a variety of industries, and expanding technical breakthroughs, are anticipated to support market expansion.
Over the projected period, the global malignant mesothelioma therapeutics market is expected to benefit from the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.
Market Dynamics
Increased Awareness Campaigns to Diagnose and Treat the Disease at an Earlier Stage will Drive the Market Growth
Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending that asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.
Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.
The Long Latency Period For Malignant Mesothelioma Is Likely To Hamper The Market Growth
A long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.
COVID-19 Impact Analysis
The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. About the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.
Segment Analysis
Pemetrexed Drug in Drug Class Segment will Dominate in the Market by Capturing 39.1% During the Forecast Period
The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibodies, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs.
These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.
Geographical Analysis
North America is the Dominating Region During the Forecast Period
In 2022, the United States is a key participant in this region, accounting for approximately 39.2% of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market size in North America is growing faster than in other areas. Advanced healthcare infrastructure is also expected to drive and contribute to the growth of the malignant mesothelioma therapeutics market in North America.
Competitive Landscape
The major global players include Dr. Reddy’s Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.
• Why Purchase the Report?
• To visualize the global malignant mesothelioma therapeutics market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by End user
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
Increased awareness campaigns to diagnose and treat the disease at an earlier stage

4.1.2. Restraints
4.1.2.1. The long latency period for malignant mesothelioma

4.1.3. Opportunity
4.1.3.1. Increasing adoption of advanced technologies
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Pemetrexed
7.2. Cisplatin
7.3. Carboplatin
7.4. Gemcitabine
7.5. Vinorelbine
7.6. Others
8. By Route of Administration
8.1. Oral
8.2. Parenteral
9. By Route of Administration
9.1 Hospitals
9.2 Cancer Centers
9.3 Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%) By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Use
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Dr. Reddy’s Laboratories,
12.2. Wellona Pharmaceuticals
12.3. Bristol-Myers Squibb
12.4. Novocure
12.5. Eli Lilly and Company
12.6. Merck
12.7. Manus Aktteva Biopharma LLP
12.8. Pfizer
12.9. Ono Pharmaceuticals
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Dr. Reddy’s Laboratories,, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer, Ono Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Malignant Mesothelioma Therapeutics Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Malignant Mesothelioma Therapeutics Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Malignant Mesothelioma Therapeutics Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Malignant Mesothelioma Therapeutics Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 8 Global Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 10 Global Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Malignant Mesothelioma therapeutics Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Malignant Mesothelioma therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 14 Global Malignant Mesothelioma Therapeutics Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 17 North America Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 North America Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Malignant Mesothelioma Therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 20 North America Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 21 North America Malignant Mesothelioma Therapeutics Market Value, By Country, 2021-2030 (US$ Million)

Table 22 South America Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 23 South America Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 24 South America Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 25 South America Malignant Mesothelioma Therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 26 South America Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 27 South America Malignant Mesothelioma Therapeutics Market Value, By Country, 2021-2030 (US$ Million)

Table 28 Europe Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 29 Europe Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Europe Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Europe Malignant Mesothelioma Therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Europe Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 33 Europe Malignant Mesothelioma Therapeutics Market Value, By Country, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 36 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, By Country, 2021-2030 (US$ Million)

Table 40 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, By Product, 2021-2030 (US$ Million)

Table 41 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 42 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, By End User, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, By Region, 2021-2030 (US$ Million)

Table 45 0: Overview

Table 46 0: Product Portfolio

Table 47 0: Key Developments

Table 48 Dr. Reddy’s Laboratories: Overview

Table 49 Dr. Reddy’s Laboratories: Product Portfolio

Table 50 Dr. Reddy’s Laboratories: Key Developments

Table 51 Wellona Pharmaceuticals: Overview

Table 52 Wellona Pharmaceuticals: Product Portfolio

Table 53 Wellona Pharmaceuticals: Key Developments

Table 54 Bristol-Myers Squibb: Overview

Table 55 Bristol-Myers Squibb: Product Portfolio

Table 56 Bristol-Myers Squibb: Key Developments

Table 57 Pfizer, Overview

Table 58 Pfizer, Product Portfolio

Table 59 Pfizer, Key Developments

Table 60 Novocure: Overview

Table 61 Novocure: Product Portfolio

Table 62 Novocure: Key Developments

Table 63 Eli Lilly and Company: Overview

Table 64 Eli Lilly and Company: Product Portfolio

Table 65 Eli Lilly and Company: Key Developments

Table 66 Merck: Overview

Table 67 Merck: Product Portfolio

Table 68 Merck, Key Developments

Table 69 Ono Pharmaceuticals.: Overview

Table 70 Ono Pharmaceuticals.: Product Portfolio

Table 71 Ono Pharmaceuticals.: Key Developments

Table 72 Manus Aktteva Biopharma: Overview

Table 73 Manus Aktteva Biopharma: Product Portfolio

Table 74 Manus Aktteva Biopharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 2 Global Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 3 Global Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By Product, 2022-2030 (%)

Figure 8 Others Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 9 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 10 Pemetrexed Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 11 Cisplatin Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 12 Carboplatin Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 13 Gemcitabine Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 14 Vinorelbine Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 15 Chemical Processing Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 16 Others Drug Class in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 17 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 18 Oral Route of Administration in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 19 Parenteral Route of Administration in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 20 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 21 Hospital Pharmacies End User in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 22 Cancer Centres End User in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 23 Others End User in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 24 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Region in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Region in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Region in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 28 South America Region in Global Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 29 Global Malignant Mesothelioma Therapeutics Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 30 North America Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 31 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 32 Europe Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 33 South America Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 34 Middle East and Africa Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 35 North America Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 36 North America Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 37 North America Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 North America Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 North America Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 40 North America Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 41 North America Malignant Mesothelioma Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 42 South America Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 43 South America Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 44 South America Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 45 South America Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 South America Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 47 South America Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 48 South America Malignant Mesothelioma Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 49 Europe Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 50 Europe Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 51 Europe Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 52 Europe Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Europe Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 54 Europe Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 55 Europe Malignant Mesothelioma Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 56 Asia-Pacific Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 57 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 58 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 59 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 60 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 61 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 62 Asia-Pacific Malignant Mesothelioma Therapeutics Market Share, By Country, 2022 & 2030 (%)

Figure 63 Middle East & Africa Malignant Mesothelioma Therapeutics Market Value, 2021-2030 (US$ Million)

Figure 64 Middle East & Africa Malignant Mesothelioma Therapeutics Market Share, By Product, 2022 & 2030 (%)

Figure 65 Middle East & Africa Malignant Mesothelioma Therapeutics Market Share, By Drug Class, 2022 & 2030 (%)

Figure 66 Middle East & Africa Malignant Mesothelioma Therapeutics Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 67 Middle East & Africa Malignant Mesothelioma Therapeutics Market Share, By End User, 2022 & 2030 (%)

Figure 68 Middle East & Africa Malignant Mesothelioma Therapeutics Market Share, By Region, 2022 & 2030 (%)

Figure 69 Dr Reddy’s Laboratories, Financials

Figure 70 Wellona Pharmaceuticals, Financials

Figure 71 Bristol-Myers Squibb, Financials

Figure 72 Pfizer, Financials

Figure 73 Novocure, Financials

Figure 74 Eli Lilly and Company, Financials

Figure 75 Merck, Financials

Figure 76 Ono Pharmaceuticals.: Financials

Figure 77 Manus Aktteva Biopharma LLP: Financials

세계 악성 중피종 치료제 시장 – 2023-2030

Global Malignant Mesothelioma Therapeutics Market - 2023-2030